within Pharmacolibrary.Drugs.ATC.C;

model C09AA11
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.00109,
    k12             = 0.12,
    k21             = 0.12
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09AA11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Spirapril is a long-acting angiotensin-converting enzyme (ACE) inhibitor used primarily in the management of hypertension and heart failure. It is usually administered as its prodrug spirapril, which is hydrolyzed in vivo to the active metabolite spiraprilat. While it was previously marketed and used clinically, spirapril has been withdrawn from several markets and is not widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Krähenbühl, S, et al., &amp; Reichen, J (1993). Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. <i>European journal of clinical pharmacology</i> 45(3) 247–253. DOI:<a href=\"https://doi.org/10.1007/BF00315391\">10.1007/BF00315391</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8276049/\">https://pubmed.ncbi.nlm.nih.gov/8276049</a></p></li><li><p>Johnson, BF, et al., &amp; Flemming, J (1991). Digoxin pharmacokinetics and spirapril, a new ace inhibitor. <i>Journal of clinical pharmacology</i> 31(6) 527–530. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1991.tb03732.x\">10.1002/j.1552-4604.1991.tb03732.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1880218/\">https://pubmed.ncbi.nlm.nih.gov/1880218</a></p></li><li><p>Noble, S, &amp; Sorkin, EM (1995). Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. <i>Drugs</i> 49(5) 750–766. DOI:<a href=\"https://doi.org/10.2165/00003495-199549050-00008\">10.2165/00003495-199549050-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7601014/\">https://pubmed.ncbi.nlm.nih.gov/7601014</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09AA11;
